Seeking Alpha

TipRanks'  Instablog

TipRanks
Send Message
TipRanks is the first online co-browser that aggregates, scrutinizes, and ranks digitally published stock recommendations. TipRanks’ Financial Accountability Engine™ transparently provides the individual investor unbiased information about the reliability, accuracy and track record of those who... More
My company:
TipRanks
My blog:
TipRanks Blog
  • Worst Recommendation Of 2013 – 80% Loss  0 comments
    Apr 30, 2013 12:08 PM | about stocks: CLSN, PPHM

    How could you avoid trusting such recommendations?

    Analyst Success Rate measured According to the S&P500 and Buy Recommendations Success

    Roth Capital Partners analyst Joseph Pantginis recommended Buy Celsion (CLSN) stock to his clients on January 22nd 2013, only to see the stock fall a record 80% by January 31st. Pantginis recommended CLSN during somewhat of a hype prior to the release of the company's ThermoDox drug approval. Pantginis particularly highlighted CLSN agreement with Hisun, a Chinese company, saying he was 'impressed' by it. To Pantginis' disappointment (or to any investor who took his recommendation) Celsion crashed and burned, as it presented less than qualifying test results January 31st.

    Pantginis, with only 11% of his BUY recommendations outperforming the SP500 as measured, failed to consider that Hisun's so called 'impressive deal' with Celsion was a conditional deal dependent upon test success, essentially committing only $5 million to begin with, to cover cash flow troubles. On a more scientific basis, Celsion jumped ahead of itself, moving from one test to another too quickly, without conducting sufficient testing to provide solid scientific, and financial, grounds for significant investment and credibility according to scientific experts. Another issue Pantginis should have noted was the large improvement (33%) over placebo Celsion drug tests needed to meet for further drug approval. Overall it seems, that Pantginis did not verify that the scientific basis of the expected drug release is of significant prior to recommending to his clients to Buy the stock.

    While Pantginis proved less capable in advising on scientific stocks in this case, investors should have known his weakness ahead of time: Just a few weeks before, on January 7th Pantginis upgraded Peregrine Pharmaceuticals Inc. (PPHM) to Buy and on the same day backed out of it with a loss of 46.1% on his recommendation. Peregrine did not have any approved drugs at the time with a less than trust worthy track record. On its previous experimental drug, PPHM publicized drug success, only to admit to scientific problems two weeks later.

    Analyst Recommendation history and Success

    It seems that problems of statistical and scientific significance are common to both of Pantginis recommendations. To avoid investing in the wrong stock, or better yet to listen to the wrong recommendation, investors must know both analyst success track record and recommendation history. If investors knew Pantginis' history, particularly in a fellow drug company, they most certainly would not have listened to his recommendation for CLSN, for now hailed as the worst recommendation of 2013 according to TipRanks analysis of over 2000 analysts' recommendations since 2009.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Additional disclosure: TipRanks manager

Back To TipRanks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Most Commented
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.